M&A

News

Ipsen charts $1.75bn course for Kartos acquisition

Ipsen has agreed to buy cancer biotech Kartos Therapeutics for $450m upfront, adding a late-stage drug in the challenging MDM2 inhibitor class.

News

Merck buys life sciences firm Bio-Techne in $11.3bn deal

Merck KGaA is poised to increase the size of its life sciences business with an $11.3 billion deal to acquire rival Bio-techne.

News

AbbVie climbs post-Allergan M&A peak with Apogee buy

AbbVie has announced its biggest acquisition since the $63 billion merger with Allergan, buying Apogee and its 'mega-blockbuster' immunology pipeline.

News

RayThera founders Qing Dong and Gene Hung

Biogen pens $1bn deal to buy immunology biotech RayThera

Biogen has agreed its second takeover deal of 2026, an acquisition of immunology start-up RayThera valued at up to $1 billion.

News

GSK pursues $10.6bn takeover of cancer biotech Nuvalent

GSK is preparing for its biggest acquisition in more than 10 years, agreeing to buy cancer drug developer Nuvalent for $10.6 billion.

News

Firefly in a jar illustration on black background

J&J lights up $1bn offer for pan-KRAS developer Firefly

Johnson & Johnson has built its presence in KRAS drugs for cancer with a $1bn deal to buy Firefly Bio and its degrader-antibody conjugate platform.

Ipsen charts $1.75bn course for Kartos acquisition

Merck buys life sciences firm Bio-Techne in $11.3bn deal

AbbVie climbs post-Allergan M&A peak with Apogee buy

Biogen pens $1bn deal to buy immunology biotech RayThera

GSK pursues $10.6bn takeover of cancer biotech Nuvalent

J&J lights up $1bn offer for pan-KRAS developer Firefly

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

M&A

Editor's Picks